Full video transcriptClick to expand
Auto-generated transcript of @weightdoc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Are ozemic babies a real thing?
- 0:02Beware of ozemic babies.
- 0:04There was a recent article that came out and said that you might have an increased risk of getting pregnant if you're on ozemic.
- 0:09The reason for that is as follows.
- 0:11Ozemic on this class of medications helps you lose weight through delayed gastricymptic, meaning food moves more slowly from the stomach to the intestines.
- 0:18You feel more full, you eat less, you lose weight.
- 0:20But that delayed gastricymptic can also affect how well absorbed your oral contraceptive pill is.
- 0:26So if it doesn't get absorbed, your ability to get pregnant may be higher.
- 0:30The short answer is yes they can be, but let's take a look at what the manufacturers are saying.
- 0:34This is from Eli Lilly. It's the prescribing information for tersepartide, which can be found online.
- 0:39And in their prescribing information, they put this recommendation that females using oral contraceptives,
- 0:44AKA the birth control pill, switched to either a non-oral contraceptive method,
- 0:49or add on a barrier method of contraceptive for four weeks after starting manjaro and for four weeks after each dose escalation.
- 0:58And this is something that Lilly actually studied.
- 1:00They looked at both Tylenol and birth control absorption.
- 1:03And what they saw was that there was decreased absorption of birth control and Tylenol the first four weeks after starting a medication and after dose increases.
- 1:13Interestingly, when you look at the prescribing information for other GLP1 medications, for example,
- 1:17this is from Novo looking at semagletide, they do not state the same observed decreased absorption of oral contraception.
- 1:26They do get the same vague warning of because of the delayed gastric emptying.
- 1:30There may be the potential to impact the absorption of medications, but they also state that this has not been observed in trials with semagletide.
- 1:39So, yeah, Ozempic and manjaro babies can definitely be a thing, and manjaro clearly states on their prescribing information that a backup method should be used those first four weeks when decreased absorption of a contraceptive pill is observed to be greatest.
- 1:55And the other thing too is that weight loss in general can improve fertility and increase the chances of you becoming pregnant.
Ozempic and birth control: what the interaction risk actually is
Quick answer
Tirzepatide's prescribing information includes an explicit, data-backed recommendation for non-oral or barrier contraception during the first four weeks of use and after each dose escalation, based on Eli Lilly's pharmacokinetic studies showing reduced oral drug absorption during peak gastric slowing. Semaglutide's prescribing information acknowledges the theoretical risk from delayed gastric emptying but states this was not observed to be clinically meaningful in their trials, making the two drugs meaningfully different in terms of documented contraceptive interaction. Patients using any GLP-1 medication who are of reproductive age should discuss contraceptive planning with their provider, particularly because weight loss-related improvements in fertility represent an additional and independent pregnancy risk factor.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Ozempic and birth control: what the interaction risk actually is, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Ozempic and birth control: what the interaction risk actually is" from Dr Jennah | WeightDoc. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide's prescribing information includes an explicit, data-backed recommendation for non-oral or barrier contraception during the first four weeks of use and after each dose escalation, based on Eli Lilly's pharmacokinetic studies showing reduced oral drug absorption during peak gastric slowing.
The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic and birth control jonathan kaplan greenscreensticker." In this clip, the useful excerpt is: "Are ozemic babies a real thing?" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tirzepatide's prescribing information includes an explicit, data-backed recommendation for non-oral or barrier contraception during the first four weeks of use and after each dose escalation, based on Eli Lilly's pharmacokinetic studies showing reduced oral drug absorption during peak gastric slowing.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tirzepatide's prescribing information includes an explicit, data-backed recommendation for non-oral or barrier contraception during the first four weeks of use and after each dose escalation, based on Eli Lilly's pharmacokinetic studies showing reduced oral drug absorption during peak gastric slowing. Semaglutide's prescribing information acknowledges the theoretical risk from delayed gastric emptying but states this was not observed to be clinically meaningful in their trials, making the two drugs meaningfully different in terms of documented contraceptive interaction. Patients using any GLP-1 medication who are of reproductive age should discuss contraceptive planning with their provider, particularly because weight loss-related improvements in fertility represent an additional and independent pregnancy risk factor.
- Mounjaro's FDA prescribing label, backed by Eli Lilly's own pharmacokinetic data, recommends backup contraception for 4 weeks after starting and after each dose escalation.
- Semaglutide's prescribing label does not document the same observed reduction in oral contraceptive absorption, according to Novo Nordisk's trial data.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Mounjaro's FDA prescribing label, backed by Eli Lilly's own pharmacokinetic data, recommends backup contraception for 4 weeks after starting and after each dose escalation.
- Semaglutide's prescribing label does not document the same observed reduction in oral contraceptive absorption, according to Novo Nordisk's trial data.
- Liraglutide, a related GLP-1 drug, did not significantly reduce oral contraceptive hormone exposure in a pharmacokinetic study (Hausner et al., 2023, Clinical Pharmacokinetics), suggesting the effect may not be uniform across the drug class.
- Weight loss improving fertility is a real and independent mechanism from gastric emptying effects, documented in PCOS populations (Legro et al., 2013, NEJM).
- All GLP-1 medications carry FDA warnings against use during pregnancy; semaglutide is specifically classified as pregnancy category X in some international labels.
- Patients on any GLP-1 medication who are not trying to conceive should proactively discuss contraceptive strategy with their prescriber, not rely on general TikTok guidance.
- The creator correctly distinguished between what Lilly's and Novo's labels actually say, which is more nuance than most viral content on this topic provides.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @weightdoc actually say?
The core claim here is that GLP-1 medications, particularly tirzepatide (Mounjaro) and semaglutide (Ozempic/Wegovy), can reduce how well oral contraceptives are absorbed by slowing gastric emptying. The creator says this may raise pregnancy risk, and that Eli Lilly's own prescribing information recommends a backup contraceptive method for four weeks after starting Mounjaro and after each dose increase. They also note that Novo Nordisk's prescribing information for semaglutide is vaguer on this point, acknowledging the theoretical risk but stating it wasn't clearly observed in their trials. The video ends with a reminder that weight loss itself can improve fertility.
That's a reasonable summary of publicly available prescribing information, delivered clearly and without much distortion. The creator is reading from actual manufacturer documents, which earns some credit here.
Does the science back this up?
Yes, largely. The pharmacokinetic concern is real, and Eli Lilly actually studied it rather than just flagging it theoretically.
Tirzepatide slows gastric emptying significantly, especially in the first weeks of use and after each dose escalation. Lilly's internal pharmacokinetic study, summarized in the FDA prescribing label, found measurably reduced absorption of both acetaminophen (used as a gastric emptying marker) and an oral contraceptive containing ethinyl estradiol and levonorgestrel during those periods. The Mounjaro prescribing information explicitly recommends a non-oral contraceptive or a barrier method for four weeks after initiation and after each dose increase. That's a manufacturer-level clinical recommendation backed by their own study data, not just theoretical caution.
For semaglutide, the evidence is less clear-cut. Novo Nordisk's prescribing label includes a general warning about delayed gastric emptying potentially affecting oral drug absorption, but states this was not observed to be clinically meaningful in semaglutide trials. A pharmacokinetic study by Hausner et al. (2023, Clinical Pharmacokinetics) found that liraglutide, a related GLP-1 drug, delayed gastric emptying but did not significantly reduce exposure to oral contraceptive hormones. Semaglutide's profile differs from liraglutide's, but the Novo data does suggest the effect may be drug-specific rather than a class-wide certainty.
What did they get wrong (or right)?
Mostly right, with one notable gap. The creator correctly distinguishes between tirzepatide and semaglutide in terms of what the prescribing information actually says, which many TikTok accounts do not bother to do.
The term "Ozempic babies" is used loosely here and conflates two separate mechanisms. The gastric emptying effect reducing contraceptive absorption is one issue. Weight loss improving fertility is a genuinely different one, well documented in the PCOS literature (Legro et al., 2013, New England Journal of Medicine). The creator mentions both but doesn't clearly separate them, which could leave viewers thinking the drug itself is doing something special to fertility beyond the pill absorption issue.
The mispronunciation of "gastric emptying" as "gastric ymptic" is cosmetic, not scientific. More substantively, the claim that "Ozempic babies can definitely be a thing" is stated with more certainty than the semaglutide data actually supports. The Mounjaro data is solid. The Ozempic data is ambiguous. Treating them as equivalent misrepresents what the evidence shows.
What should you actually know?
If you're on Mounjaro (tirzepatide), the backup contraception recommendation is not vague advice. It comes from Lilly's own pharmacokinetic data and is written into the FDA label. Four weeks after starting and four weeks after every dose increase. Use a non-oral method or add a barrier method during those windows.
If you're on semaglutide (Ozempic, Wegovy), the risk is theoretical and less well-documented. That doesn't mean ignore it, but it's not the same level of evidence. Talk to your prescriber.
The weight loss and fertility connection is real and independent of any pill absorption issue. Studies in women with PCOS show meaningful improvements in ovulation and pregnancy rates with even modest weight loss. If you're using a GLP-1 medication and not actively trying to conceive, contraceptive planning deserves a real conversation with your provider, not a TikTok comment.
- Mounjaro: backup contraception is FDA-label guidance backed by Lilly's own study data
- Ozempic/Wegovy: risk is theoretical per Novo's label; their trials did not observe significant contraceptive absorption reduction
- Weight loss independently improves fertility, a separate mechanism from gastric emptying effects
- No GLP-1 drug has been proven safe in pregnancy; semaglutide carries an FDA warning against use during pregnancy
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr Jennah | WeightDoc · TikTok creator
199.6K views on this video
Ozempic and birth control @Jonathan Kaplan #greenscreensticker
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about mounjaro's fda prescribing label, backed by eli lilly's own pharmacokinetic?
Mounjaro's FDA prescribing label, backed by Eli Lilly's own pharmacokinetic data, recommends backup contraception for 4 weeks after starting and after each dose escalation.
What does the video say about semaglutide's prescribing label does not document the same observed reduction?
Semaglutide's prescribing label does not document the same observed reduction in oral contraceptive absorption, according to Novo Nordisk's trial data.
What does the video say about liraglutide, a related glp-1 drug, did not significantly reduce?
Liraglutide, a related GLP-1 drug, did not significantly reduce oral contraceptive hormone exposure in a pharmacokinetic study (Hausner et al., 2023, Clinical Pharmacokinetics), suggesting the effect may not be uniform across the drug class.
What does the video say about weight loss improving fertility?
Weight loss improving fertility is a real and independent mechanism from gastric emptying effects, documented in PCOS populations (Legro et al., 2013, NEJM).
What does the video say about all glp-1 medications carry fda warnings against use during pregnancy;?
All GLP-1 medications carry FDA warnings against use during pregnancy; semaglutide is specifically classified as pregnancy category X in some international labels.
What does the video say about patients on any glp-1 medication who?
Patients on any GLP-1 medication who are not trying to conceive should proactively discuss contraceptive strategy with their prescriber, not rely on general TikTok guidance.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr Jennah | WeightDoc, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.